The pricing outcomes negotiated in these agreements will likely have a far bigger impact on access outcomes than anything implemented as a result of the Health Technology Assessment Review. …
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
A shorter name and bolder blue for Novo in global rebrand
September 15, 2026 - - Latest News -
Australia's 2026 flu vaccination season barely moves the needle on uptake
September 15, 2026 - - Latest News -
Persistent fatigue could be an overlooked sign of liver disease
September 15, 2026 - - Latest News -
Noxopharm moves lupus skin therapy toward next human trial
September 14, 2026 - - Australian Biotech -
Entropy's psychedelic infusion keeps binge eating disorder at bay three months after treatment ends
September 14, 2026 - - Latest News -
Diabetes and cancer blood tests reach WA and NT patients under new Healius deal
September 14, 2026 - - Australian Biotech -
FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug
September 14, 2026 - - Australian Biotech